PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes

被引：3
作者：
Marx, Nikolaus [1 ]
机构：
[1] Univ Ulm, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany
来源：
DIABETES & VASCULAR DISEASE RESEARCH | 2008年 / 5卷 / 04期
关键词：
D O I：
10.3132/dvdr.2008.048
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：345 / 346
页数：2
相关论文
共 7 条
[1]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[2]   Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus [J].
Haffner, SM ;
Greenberg, AS ;
Weston, WM ;
Chen, HZ ;
Williams, K ;
Freed, MI .
CIRCULATION, 2002, 106 (06) :679-684
[3]   Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease [J].
Marx, N ;
Froehlich, J ;
Siam, L ;
Ittner, J ;
Wierse, G ;
Schmidt, A ;
Scharnagl, H ;
Hombach, V ;
Koenig, W .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) :283-288
[4]   Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial [J].
Mazzone, Theodore ;
Meyer, Peter M. ;
Feinstein, Steven B. ;
Davidson, Michael H. ;
Kondos, George T. ;
D'Agostino, Ralph B., Sr. ;
Perez, Alfonso ;
Provost, Jean-Claude ;
Haffner, Steven M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (21) :2572-2581
[5]   Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial [J].
Nissen, Steven E. ;
Nicholls, Stephen J. ;
Wolski, Kathy ;
Nesto, Richard ;
Kupfer, Stuart ;
Perez, Alfonso ;
Jure, Horacio ;
De Larochelliere, Robert ;
Staniloae, Cezar S. ;
Mavromatis, Kreton ;
Saw, Jacqueline ;
Hu, Bo ;
Lincoff, A. Michael ;
Tuzcu, E. Murat .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (13) :1561-1573
[6]   Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus [J].
Sidhu, JS ;
Kaposzta, Z ;
Markus, HS ;
Kaski, JC .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) :930-934
[7]   The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients [J].
Sidhu, JS ;
Cowan, D ;
Kaski, JC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (10) :1757-1763
1